SyntaxBio: Funding, Investors & Team (Oct 2026)

Syntax Bio is a synthetic biology and biotechnology company that develops a CRISPR-based cell programming platform designed to control and accelerate stem cell differentiation for research and therapeutic applications. The company builds a proprietary system called Cellgorithm, which uses programmable genetic instructions to guide stem cells into specific functional cell types more efficiently than traditional stepwise chemical or growth-factor methods. Its platform mimics natural human developmental processes by delivering timed, sequential genetic signals that regulate how cells activate or suppress specific genes during differentiation. This approach is intended to improve reproducibility and scalability in the production of stem cell–derived therapies, reducing variability that often occurs in conventional lab-based differentiation workflows. Syntax Bio works with biopharmaceutical and research partners to apply its technology in areas such as regenerative medicine, drug discovery, and cell therapy manufacturing. The platform is positioned as a tool that can accelerate the creation of specialized cell types used in therapeutic development, potentially shortening timelines for preclinical research and improving consistency in cell production processes.

SyntaxBio has raised $14.4M across 1 round on record. The most recent is a Series A of $14.4M announced in Jun 2026.

SyntaxBio's most recent funding round on record is a Series A of $14.4M, announced in Jun 2026.

FundedIQ lists John Craighead (Founder) at SyntaxBio.

SyntaxBio is based in Chicago, Illinois, United States.

SyntaxBio is in the 11-50 employee band.

SyntaxBio's latest round of $14.4M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.